Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan

Citation
I. Nestorov et al., Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan, PHARM RES, 18(8), 2001, pp. 1210-1219
Citations number
23
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology & Toxicology
Journal title
PHARMACEUTICAL RESEARCH
ISSN journal
0724-8741 → ACNP
Volume
18
Issue
8
Year of publication
2001
Pages
1210 - 1219
Database
ISI
SICI code
0724-8741(200108)18:8<1210:MASFCT>2.0.ZU;2-A
Abstract
Purpose. The overall aim of the present study was to investigate retrospect ively the feasibility and utility of model-based clinical trial simulation as applied to the clinical development of naratriptan with effect measured on a categorical scale. Methods. A PK-PD model for naratriptan was developed by using information g athered from previous naratriptan and sumatriptan preclinical and clinical trials. The phase IIa naratriptan data were used to check the PK-PD model i n its ability to describe future data. A further PK-PD model was developed by using the phase IIa naratriptan data, and a phase IIb trial was designed by simulation with the use of Matlab. The design resulting from clinical t rial simulation was compared with that derived by using D-optimal design. Results. The PK-PD model showed reasonable agreement with the data observed in the phase IIa naratriptan clinical trial. Clinical trial simulation res ulted in a design with four or five arms at 0 mg, 2.5 and/or 5 mg, 10 mg, a nd 20 mg, PD measurements to be taken at 0, 2, and 4 or 6 li and at least 1 50 patients per arm, A sub-D-optimal design resulted in two dosing arms at 0 and 10 mg and PD measurements to be taken at I and 2 h. Conclusions. Clinical trial simulation is a useful tool for the quantitativ e assessment of the influence of the controllable factors and is the only t ool for the quantitative assessment of the uncontrollable factors on the po wer of a clinical trial.